The acceptability and effectiveness of chocolate or tomato extract in reducing blood pressure in people with pre-hypertension: a pilot study.
Phase 4
Completed
- Conditions
- Pre-hypertensionCardiovascular - HypertensionCardiovascular - Coronary heart disease
- Registration Number
- ACTRN12609000047291
- Lead Sponsor
- Dr Oliver Frank
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Blood pressure 120-139/80-89 mm Hg
Exclusion Criteria
Currently on treatment for hypertension;
Diabetic or glucose intolerant;
Allergic to or intolerant of tomato or cocoa
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Acceptability of each treatment using questionnaires[at 8 and 20 weeks];Reduction in blood pressure[at 0, 4, 8, 12, 16, 20, 24 weeks]
- Secondary Outcome Measures
Name Time Method physical activity by questionnaire[0,8,20 weeks];general health, mood, energy by questionnaire[0,8,20 weeks]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the blood pressure-lowering effects of cocoa flavanols and lycopene in pre-hypertension (ACTRN12609000047291)?
How does cocoa flavanol supplementation compare to ACE inhibitors in managing pre-hypertension (ACTRN12609000047291)?
Which oxidative stress biomarkers predict response to tomato extract or chocolate interventions in pre-hypertensive patients?
What adverse events are associated with cocoa flavanol and lycopene therapies versus standard antihypertensive drugs?
Are there synergistic effects when combining cocoa flavanols with omega-3 fatty acids for pre-hypertension treatment?